Disease Surveillance Regulations

Regulation
Registration
R-096-2009
Source
Unofficial consolidation PDF (justice.gov.nt.ca)
Under
Public Health Act

This is an unofficial reading copy parsed from the Department of Justice consolidation PDF above — itself an office consolidation, not an official statement of the law. The authoritative text is in the Revised Statutes of the Northwest Territories, 1988 and the annual Statutes volumes.

  • s.1 amended by R-075-2016,s.2 in force Aug. 1, 2016 (SI-008-2016)
  • s.1 amended by R-073-2023,s.2 in force Dec. 1, 2023
  • s.3 amended by R-073-2023,s.3 in force Dec. 1, 2023
  • s.5 amended by R-073-2023,s.4 in force Dec. 1, 2023
  • s.7 amended by R-073-2023,s.5 in force Dec. 1, 2023
  • s.7 amended by R-052-2024,s.2 in force July 31, 2024
  • s.8 amended by R-073-2023,s.5 in force Dec. 1, 2023
  • s.8 amended by R-052-2024,s.3 in force July 31, 2024
  • s.10 amended by R-073-2023,s.6 in force Dec. 1, 2023
  • s.10.1 amended by R-073-2023,s.7 in force Dec. 1, 2023
  • s.11 amended by R-088-2015,s.2 in force Jan. 1, 2016
  • s.11 amended by R-073-2023,s.8 in force Dec. 1, 2023
  • s.12 repealed by R-073-2023,s.9 in force Dec. 1, 2023
  • s.13 amended by R-073-2023,s.10 in force Dec. 1, 2023
  • s.14 repealed by R-068-2011,s.5
  • s.15 repealed by R-068-2011,s.5
  • s.sched_1 amended by R-073-2023,s.11 in force Dec. 1, 2023
  • s.sched_2 amended by R-073-2023,s.12 in force Dec. 1, 2023
  • s.sched_3 amended by R-073-2023,s.13 in force Dec. 1, 2023
  • s.sched_3 amended by R-034-2024,s.2
  • s.sched_4 amended by R-073-2023,s.14 in force Dec. 1, 2023
  • s.sched_5 amended by R-073-2023,s.15 in force Dec. 1, 2023

The Commissioner, on the recommendation of the Minister, under section 50 of the Public Health Act and every enabling power, makes the Disease Surveillance Regulations.

Interpretation

1.

In these regulations,

"health care number" means an identifying number, symbol or other particular assigned to a person in respect of health services or health information; (numéro de soins de santé)

"health facility" means a facility that provides health services pursuant to the Hospital Insurance and Health and Social Services Administration Act; (établissement de santé)

"outbreak" means an increase in the number of cases of a disease above the expected rate; (éclosion)

"register" means a register established by the Chief Public Health Officer under subsection 24(1) of the Act. (registre) R-075-2016,s.2; R-073-2023,s.2.

Notifiable Diseases and Conditions

2.

The diseases and conditions that are listed or referred to in Schedule 1 are prescribed as notifiable diseases or conditions.

3.

(1) If a health care professional diagnoses a notifiable disease or condition in a person, or is of the opinion, on reasonable grounds, that a person who the health care professional examines or treats has a notifiable disease or condition, the health care professional shall provide the following information to the Chief Public Health Officer:

(a) the name, place of residence, place of birth, date of birth, ethnicity, sex assigned at birth and health care number of the person;

(b) in the case of a notifiable disease or condition listed in Part 2 of Schedule 1, the name, place of residence, place of birth, date of birth, ethnicity and health care number of each biological parent of the person;

(c) the name of the notifiable disease or condition;

(d) the clinical and epidemiological details relevant to the diagnosis and treatment;

(e) the name and profession of, and the contact information for

(i) the health care professional who made the diagnosis or formed the opinion, and

(ii) the person providing the information, if other than the health care professional;

(f) any additional information the Chief Public Health Officer requires in respect of the person or the notifiable disease or condition, for the purposes of public health surveillance and health promotion.

(2) A requirement to provide any of the information referred to in subsection (1) does not apply if the Chief Public Health Officer determines that the information is not required in respect of a particular notifiable disease or condition.

(3) The information referred to in this section must be provided within three months after the day the diagnosis is made or the opinion is formed, in a form and manner approved by the Chief Public Health Officer. R-073-2023,s.3.

Notifiable Tests

4.

The tests listed in Schedule 2 for notifiable diseases or conditions are prescribed as notifiable tests.

5.

(1) If a health care professional performs a notifiable test, or causes a notifiable test to be performed, the health care professional shall provide the following information to the Chief Public Health Officer:

(a) the name, place of residence, place of birth, date of birth, ethnicity, sex assigned at birth and health care number of the person in respect of whom the test is conducted;

(b) the result of the test;

(c) the name and profession of, and the contact information for

(i) the health care professional who performed the test or caused the test to be performed, and

(ii) the person providing the information, if other than the health care professional;

(d) any additional information the Chief Public Health Officer requires in respect of the test or the person being tested, for the purposes of public health surveillance and health promotion.

(2) A requirement to provide any of the information referred to in subsection (1) does not apply if the Chief Public Health Officer determines that the information is not required

(a) in respect of a particular notifiable test; or

(b) for a negative result in respect of a particular notifiable test.

(3) The information referred to in this section must be provided within three months after the day the result is obtained, in a form and manner approved by the Chief Public Health Officer. R-073-2023,s.4.

Reportable Diseases

6.

The communicable diseases and other health conditions listed in Schedule 3 are prescribed as reportable diseases.

7.

(1) In this section and section 8, "Communicable Disease Manual" means the NWT Communicable Disease Manual, established by the Chief Public Health Officer, as amended from time to time.

(2) If a health care professional diagnoses a reportable disease or condition in a person, or is of the opinion, on reasonable grounds, that a person who the health care professional examines or treats has a reportable disease or condition, the health care professional shall, in accordance with this section and unless otherwise directed by the Chief Public Health Officer, provide the Chief Public Health Officer with the information required by the Communicable Disease Manual for that disease or condition.

(3) If the health care professional diagnoses or forms an opinion that a person is infected with a disease listed in Part 1 of Schedule 3, the health care professional shall

(a) immediately notify the Chief Public Health Officer by telephone of the diagnosis or opinion; and

(b) provide the information referred to in subsection (2) within 24 hours after the diagnosis is made or the opinion is formed, in the form and manner set out in the Communicable Disease Manual, unless otherwise directed by the Chief Public Health Officer.

(4) If the health care professional diagnoses or forms an opinion that a person is infected with a disease listed in Part 2 of Schedule 3, the information referred to in subsection (2) must be provided within 24 hours after the diagnosis is made or the opinion is formed, in the form and manner set out in the Communicable Disease Manual, unless otherwise directed by the Chief Public Health Officer.

(5) If the health care professional diagnoses or forms an opinion that a person is infected with a disease listed in Part 3 of Schedule 3, the information referred to in subsection (2) must be provided within seven days after the diagnosis is made or the opinion is formed, in the form and manner set out in the Communicable Disease Manual, unless otherwise directed by the Chief Public Health Officer.

(6) A person in charge of a health facility where a person with a reportable disease or suspected reportable disease is examined, tested or treated shall take the necessary measures to ensure that the information referred to in subsection (2) is provided to the Chief Public Health Officer in accordance with these regulations, and shall provide the Chief Public Health Officer with the required information within the required time if circumstances prevent a health care professional from doing so. R-073-2023,s.5; R-052-2024,s.2.

8.

(1) If a health care professional performs or interprets a diagnostic imaging test or other medical diagnostic test in a health facility or medical laboratory, and is of the opinion, on reasonable grounds, that the result indicates that the subject of the test has a reportable disease, the health care professional shall, in accordance with this section and unless otherwise directed by the Chief Public Health Officer, provide the Chief Public Health Officer with the information required by the Communicable Disease Manual for that disease or condition.

(2) If the health care professional is of the opinion that the test result indicates that the subject has a reportable disease listed in Part 1 of Schedule 3, the health care professional shall

(a) immediately notify the Chief Public Health Officer by telephone of the test result and opinion; and

(b) provide the information referred to in subsection (1) within 24 hours after the opinion is formed, in the form and manner set out in the Communicable Disease Manual, unless otherwise directed by the Chief Public Health Officer.

(3) If the health care professional is of the opinion that the test result indicates that the subject has a reportable disease listed in Part 2 of Schedule 3, the information referred to in subsection (1) must be provided within 24 hours after the opinion is formed, in the form and manner set out in the Communicable Disease Manual, unless otherwise directed by the Chief Public Health Officer.

(4) If the health care professional is of the opinion that the test result indicates that the subject has a reportable disease listed in Part 3 of Schedule 3, the information referred to in subsection (1) must be provided within seven days after the opinion is formed, in the form and manner set out in the Communicable Disease Manual, unless otherwise directed by the Chief Public Health Officer. R-073-2023,s.5; R-052-2024,s.3.

Reportable Tests

9.

The tests listed in Schedule 4 for reportable diseases are prescribed as reportable tests.

10.

(1) If a health care professional performs a reportable test, or causes a reportable test to be performed, the health care professional shall provide the following information to the Chief Public Health Officer:

(a) the name, place of residence, place of birth, date of birth, ethnicity, sex assigned at birth and health care number of the person in respect of whom the test is conducted;

(b) the result of the test;

(c) the name and profession of, and the contact information for

(i) the health care professional who performed the test or caused the test to be performed, and

(ii) the person providing the information, if other than the health care professional;

(d) any additional information the Chief Public Health Officer requires in respect of the test or the person being tested, for the purposes of public health surveillance and health protection.

(2) A requirement to provide any of the information referred to in subsection (1) does not apply if the Chief Public Health Officer determines that the information is not required

(a) in respect of a particular reportable test; or

(b) for a negative result in respect of a particular reportable test.

(3) The information referred to in this section must be provided within three months after the day the result is obtained, in a form and manner approved by the Chief Public Health Officer. R-073-2023,s.6.

10.1.

If the Chief Public Health Officer is of the opinion that there has been an outbreak of a reportable disease that does not have a reportable test, the Chief Public Health Officer may, with respect to that disease, require health care professionals to report disease test numbers and results to the Chief Public Health Officer

(a) immediately after a test result is confirmed; and

(b) in a form and manner approved by the Chief Public Health Officer.

R-073-2023,s.7.

Registers

11.

(1) The following registers, established by the Chief Public Health Officer, must be maintained in a form satisfactory to the Chief Public Health Officer:

(a) the Cancer Register;

(b) the Cancer Screening Register;

(c) the Congenital Anomalies Register;

(d) the Chronic Disease Register;

(e) the Reportable Diseases Register;

(f) any other register established by the Chief Public Health Officer under section 24 of the Act.

(2) The Chief Public Health Officer shall ensure that registers are updated regularly to include information provided in respect of

(a) notifiable diseases or conditions;

(b) notifiable tests;

(c) reportable diseases; and

(d) reportable tests.

R-088-2015,s.2; R-073-2023,s.8.

12.

Repealed, R-073-2023,s.9.

Food Establishment Workers

13.

(1) A food establishment worker, as defined in the Food Establishment Safety Regulations, who is infected with or has been exposed to a disease listed in Schedule 5, shall not perform any function in a food establishment that involves contact with food, food contact surfaces, equipment, utensils, other food establishment workers who perform such functions or clients.

(2) The prohibition set out in subsection (1) terminates in respect of a food establishment worker upon

(a) written confirmation from a medical practitioner that the worker is not infected with the disease;

(b) proof of a valid negative test result for the disease, performed on the worker after the date the worker was infected with or exposed to the disease; or

(c) written authorization from the Chief Public Health Officer.

R-073-2023,s.10.

14.

Repealed, R-068-2011,s.5.

15.

Repealed, R-068-2011,s.5.

SCHEDULE 1 (sections 2 and 3)

NOTIFIABLE DISEASES AND CONDITIONS

Part 1 Cancers and Benign Tumours

1. The primary, malignant, in-situ, borderline malignant cancers and the benign tumours of the brain and nervous system listed in the International Classification of Diseases for Oncology, Third Edition (ICD-O-3), established by the World Health Organization, as amended from time to time.

Part 2 Congenital Anomalies

The conditions listed in the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10-CA),Volume One - Tabular List, published by the Canadian Institute for Health Information in June 2006, and as the references to those conditions may be amended from time to time, including the following conditions:

Item No. Notifiable Disease or Condition ICD-10-CA Code

1. Congenital syphilis A50.0 to A50.9

2. Hereditary haemolytic anemias D55.0 to D58.9

3. Constitutional aplastic anemia D61.0

4. Disorders involving the immune mechanism D80.0 to D84.9,

D89.8, D89.9

5. Congenital hypothyroidism E00.0 to E00.9

6. Adrenogenital disorders E25.0 to E25.9

7. Other endocrine disorders if congenital or genetic E34.0 to E34.9

8. Disorders of amino acid metabolism E70.0 to E72.9

9. Glycogenosis and galactosemia E74.0, E74.2

10. Other and unspecified disorders of metabolism E76.0 to E76.9, E78.0 to E78.9, E79.0 to E79.9, E80.0 to E80.7, E84.0 to E85.9,

E88.0, E88.8, E88.9

11. Childhood autism F84.0

12. Hereditary ataxia G11.1 to G11.9

13. Spinal muscular atrophy and related syndromes G12.0 to G12.9

14. Other degenerative diseases and disorders of nervous system G31.8, G31.9, G60.0 to G60.9, G91.0, G91.1, G93.7, G94.0 to

G94.8

15. Muscular dystrophies and other myopathies G71.0 to G72.9

16. Primary disorders of muscles G71.0 to G71.9

17. Cerebral palsy G80.0 to G80.9

18. Familial dysautonomia (Riley-Day) G90.1

19. Hereditary retinal dystrophy H35.5

20. Conductive and sensorineural hearing loss H90.0 to H90.8, H91.3, H91.8,

H91.9

21. Inguinal hernia K40.0 to K40.9

22. Femoral hernia K41.0 to K41.9

23. Pilonidal cyst and sinus L05.0 to L05.9

24. Other disorders of pigmentation L81.0 to L81.9

25. Fetus and newborn affected by maternal infectious and parasitic P00.2 diseases

26. Fetus and newborn affected by other maternal conditions P00.8

27. Newborn (suspected to be) affected by complications of placenta, P02.0 to P02.9 cord and membranes

28. Fetus and newborn affected by maternal medication P04.1

29. Fetus and newborn affected by maternal use of tobacco P04.2

30. Fetus and newborn affected by maternal use of alcohol P04.3

31. Fetus and newborn affected by maternal use of drugs of addiction P04.4

32. Fetus and newborn affected by maternal use of nutritional P04.5 chemical substances

33. Fetus and newborn affected by maternal exposure to P04.6 environmental chemical substances

34. Fetus and newborn affected by other maternal noxious influences P04.8

35. Fetus and newborn affected by maternal noxious influences, P04.9 unspecified

36. Congenital viral diseases (newborns of age 0 years only) P35.0 to P35.9

37. Other congenital infectious and parasitic diseases P37.0 to P37.9

38. Other conditions originating in the perinatal period P96.0 to P96.9

39. Anencephaly and similar malformations Q00.0 to Q00.2

40. Other congenital malformations of brain Q01.0 to Q04.9

41. Spina bifida Q05.0 to Q05.9

42. Other congenital malformations of spinal cord Q06.0 to Q06.9

43. Other congenital malformations of nervous system Q07.0 to Q07.9

44. Congenital malformations of eye Q10.0 to Q15.9

45. Congenital malformations of ear, face and neck Q16.0 to Q18.9

46. Congenital anomalies of heart Q20.0 to Q24.9

47. Congenital malformations of circulatory system Q25.0-Q28.9

48. Congenital malformations of respiratory system Q30.0 to Q34.9

49. Cleft lip and cleft palate Q35.1 to Q37

50. Other congenital malformations of the digestive system Q38.0 to Q45.9

51. Congenital malformations of genital organs Q50.0 to Q56.4

52. Congenital malformations of urinary system Q60.0 to Q64.9

53. Congenital malformations and deformations of musculoskeletal Q65.0 to Q79.9 system

54. Other congenital malformations Q80.0 to Q89.9

55. Congenital malformations of the integument Q80.0 to Q84.9

56. Neurofibromatosis (non-malignant) Q85.0

57. Tuberous sclerosis Q85.1

58. Other phakomatoses Q85.8, Q85.9

59. Fetal alcohol syndrome (dysmorphic) Q86.0

60. Congenital malformation syndromes due to known exogenous Q86.1 to Q89.9 causes

61. Chromosomal abnormalities, not elsewhere classified Q90.0 to Q99.9 Part 3

Chronic Diseases

The following diseases, as listed in the Canadian Chronic Disease Surveillance System (CCDSS), Table 1: Diseases, conditions and indicators included in the CCDSS, published by the Public Health Agency of Canada, and as the references to those diseases may be amended from time to time.

Item No. Notifiable Disease or Condition ICD-10-CA Code

1. Acute myocardial infraction (AMI) I21, I22

2. Heart failure I50

3. Hypertension excluding gestational hypertension I10, I11, I12, I13, I15

4. Ischemic heart disease G08, G45.x (exclude G45.4), H34.0, H34.1, I60.x, I61.x, I62.9, I63.x, I64, I67.6

5. Stroke G08, G45.x (exclude G45.4), H34.0, H34.1, I60.x, I61.x, I62.9, I63.x, I64, I67.6

6. Asthma J45, J46

7. Chronic obstructive pulmonary disease J41, J42, J43, J44

8. Diabetes mellitus including Type 1, Type 2, other specified, E10, E11, E13, E14, O24.4 unspecified diabetes mellitus, and diabetes mellitus in pregnancy

9. Mental illness and alcohol/drug induced disorders F04-F99

10. Mood and anxiety disorders F30-F42, F44-F48, F68

11. Schizophrenia F20, F21, F23, F25

12. Arthritis L40.5, M10, M00-M03, M11,

M07, M14, M36.1, M36.2,

M36.3, M36.4, M05-M06,

M15-M19, M22.4, M12.0,

M12.1, M12.2, M12.3, M12.4,

M12.8, M13, M45, M46.1,

M46.8, M46.9, M47.1, M47.2,

M47.8, M47.9, M48.1, M48.2,

M48.8, M48.9, M49, M35.3

13. Gout and other crystal arthropathies M10, M11

14. Juvenile idiopathic arthritis M05, M06, M07.0, M07.1,

M07.2, M07.3, M08, M45

15. Osteoarthritis M15-M19

16. Rheumatoid arthritis M05-M06

17. Osteoporosis, including osteoporosis-related fractures M80, M81; S52, S62, S32,

S32.1, S32.3, S32.4, S32.5,

S42, S42.2, S42.3, S42.4, S22,

S22.0, S22.1, S32.0

18. Dementia, including Alzheimer disease G30, F00, F01, F02, F03

19. Epilepsy G40

20. Multiple sclerosis G35

21. Parkinsonism, including Parkinson disease F02.3, G20, G21

R-073-2023,s.11.

SCHEDULE 2 (sections 4 and 5)

NOTIFIABLE TEST

Part 1

1. Any procedure or test undertaken on an individual for the purposes of screening for, or diagnosing, any type of cancer listed in the International Classification of Diseases for Oncology, published by the World Health Organization, as amended from time to time

2. Any procedure or test undertaken on an individual for the purposes of screening for, or diagnosing, any disease listed in Table 1 of the 2018 Clinical Practice Guidelines, Definition, Classification and Diagnosis of Diabetes, Prediabetes and Metabolic Syndrome, published in the Canadian Journal of Diabetes by the Diabetes Canada Clinical Practice Guidelines Expert Committee in April 2018, as amended from time to time

R-073-2023,s.12.

SCHEDULE 3

(sections 6, 7 and 8)

REPORTABLE DISEASES

Part 1

1. Acute flaccid paralysis

2. Anthrax

3. Botulism

4. Cholera

5. Diseases caused by a novel coronavirus, including severe acute respiratory syndrome (SARS), middle east respiratory syndrome (MERS) and severe outcomes of SARS-CoV-2 (COVID-19)

6. Food poisoning outbreaks, including communicable enteric infections

7. Gastroenteritis epidemic, including institutional outbreaks

8. Group A streptococcal infections, invasive, including toxic shock syndrome, necrotizing fasciitis, myositis and pneumonitis

9. Haemophilus influenzae type B infections, invasive (Hib)

10. Hantaviral disease (hantavirus pulmonary syndrome)

11. Hemorrhagic fevers, including Ebola, Marburg virus, lassa virus and Sudan virus

12. Hepatitis A

13. Hepatitis E

14. Highly pathogenic avian influenza, including H5N1 and H7N2

15. Listeriosis

16. Measles

17. Meningitis acute

18. Meningococcal disease invasive

19. Orthopoxvirus, including Mpox and small pox

20. Plague

21. Poliomyelitis

22. Rabies or exposure to rabies

23. Respiratory diphtheria

24. Rubella, including congenital syndrome

25. Shiga toxin-producing Escherichia coli (STEC) 0157, verotoxin-producing Escherichia coli infection indicator conditions, including 0157:H7 and hemolytic uremic syndrome

26. Shigellosis

27. Trichinosis

28. Tuberculosis disease

29. Typhoid and paratyphoid fevers

30. Epidemic forms or outbreaks of any disease, including new and emerging infectious diseases

Part 2

1. Aeromonas

2. Acquired immunodeficiency syndrome (AIDS)

3. Amoebiasis

4. Brucellosis

5. Campylobacteriosis

6. Chancroid

7. Chlamydial infections

8. Cryptosporidiosis

9. Cutaneous diphtheria

10. Cyclospora

11. Encephalitis

12. Giardiasis

13. Gonococcal infections

14. Group B streptococcal infections invasive, neonatal

15. Hepatitis B

16. Hepatitis C

17. Human immunodeficiency virus (HIV) infections

18. Influenza

19. Legionellosis

20. Leprosy

21. Mumps

22. Parvovirus B19

23. Pertussis (whooping cough)

24. Pneumococcal disease, invasive

25. Prion disease, including Creutzfeldt Jakob-disease

26. Respiratory syncytial virus (RSV)

27. Salmonellosis

28. SARS-CoV-2 [COVID-19] (not severe)

29. Syphilis

30. Tetanus

31. Toxoplasmosis

32. Tularemia

33. Varicella (chicken pox)

34. Vector borne diseases, including anaplasmosis, babesiosis, California serogroup viruses, chikungunya, dengue, Japanese encephalitis, malaria, Powassan virus disease, West Nile, yellow fever and zika

35. Yersiniosis

36. Unusual clinical manifestations of any disease

Part 3

1. Antibiotic-resistant organisms (AROs), including Acinetobacter baumannii, CRO, ESBL, MRSA, Penicillin-resistant streptococcal pneumonia, VRSA, Vancomycin-resistant enterococci

2. Clostridium difficile associated disease

3. Coxiella burnetii (Q fever)

4. Cytomegalovirus infection, congenital

5. Erysipelothrix

6. Herpes simplex, congenital or neonatal

7. Human T-cell lymphotropic virus infections

8. Lyme disease

9. Psittacosis/Ornithosis

10. Tapeworm infestations, including echinococcal disease

11. Tuberculosis infections

R-073-2023,s.13; R-034-2024,s.2.

SCHEDULE 4

(sections 9 and 10)

REPORTABLE TESTS

1. Human immunodeficiency virus (HIV) tests

2. Rubella tests

3. Any procedure or test undertaken on an individual for the purposes of screening for, or diagnosing, tuberculosis, including tuberculin skin tests and Interferon Gamma Release Assays

4. Syphilis tests, including point-of-care tests

R-073-2023,s.14.

SCHEDULE 5 (section 13)

FOOD ESTABLISHMENT WORKER

PROHIBITION DISEASES

1. Amoebiasis

2. Campylobacteriosis

3. Cholera

4. Cryptosporidiosis

5. Cyclospora

6. Diphtheria

7. Shiga toxin-producing Escherichia coli (STEC)

8. Giardia

9. Hepatitis A

10. Listeriosis

11. Salmonellosis

12. Shigellosis

13. Yersiniosis

R-073-2023,s.15.

Help us improve OpenNWT